Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Feature Previous | All Articles This Week | Next
This article originally posted 24 June, 2011 and appeared in  Medication, Issue 579

BYDUREON™ Receives Marketing Authorization in Europe

BYDUREON™ Receives Marketing Authorization in Europe

BYDUREON showed statistically significant improvements in glycemic control based on reduction of A1C (a measure of average blood sugar over three months) between 1.5 and 1.9 percent after six months.
Advertisement

Related Articles

FDA Approves Two Generics of Clopidogrel (Plavix) FDA Approves Labeling Changes for All Statins Two New Weight Loss Drugs Approved by FDA Advisory Committee
Advertisement

 

Bookmark and Share | Print | Category | Home

This article originally posted 24 June, 2011 and appeared in  Medication, Issue 579

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control

Complications CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews

Announcement:
 

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes

Search Articles On Diabetes In Control